A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice

被引:388
作者
Chen, JF
Huang, ZH
Ma, JY
Zhu, JM
Moratalla, R
Standaert, D
Moskowitz, MA
Fink, JS
Schwarzschild, MA
机构
[1] Massachusetts Gen Hosp, Dept Neurol & Neurosci, Mol Neurobiol Lab, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Neurol & Neurosci, Stroke & Neurovasc Regulat Lab, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Neurol & Neurosurg, Neurol Res Lab, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA 02114 USA
关键词
A(2A) adenosine receptor; ischemia; stroke; purine receptor; knock-out; neuroprotection;
D O I
10.1523/jneurosci.19-21-09192.1999
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Extracellular adenosine critically modulates ischemic brain injury, at least in part through activation of the A(1) adenosine receptor. However, the role played by the A(2A) receptor has been obscured by intrinsic limitations of A(2A) adenosinergic agents. To overcome these pharmacological limitations, we explored the consequences of deleting the A(2A) adenosine receptor on brain damage after transient focal ischemia. Cerebral morphology, as well as vascular and physiological measures (before, during, and after ischemia) did not differ between A(2A) receptor knock-out and wild-type littermates. The volume of cerebral infarction, as well as the associated neurological deficit induced by transient filament occlusion of the middle cerebral artery, were significantly attenuated in A(2A) receptor knock-out mice. This neuroprotective phenotype of A(2A) receptor-deficient mice was observed in different genetic backgrounds, confirming A(2A) receptor disruption as its cause. Together with complimentary pharmacological studies, these data suggest that A(2A) receptors play a prominent role in the development of ischemic injury within brain and demonstrate the potential for anatomical and functional neuroprotection against stroke by A(2A) receptor antagonists.
引用
收藏
页码:9192 / 9200
页数:9
相关论文
共 55 条
  • [31] Pharmacology of adenosine A(2A) receptors
    Ongini, E
    Fredholm, BB
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (10) : 364 - 372
  • [32] Comparison of CGS15943, ZM241385 and SCH58261 as antagonists at human adenosine receptors
    Ongini, E
    Dionisotti, S
    Gessi, S
    Irenius, E
    Fredholm, BB
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (01) : 7 - 10
  • [33] THE SELECTIVE ADENOSINE-A2 RECEPTOR AGONIST CGS 21680 ENHANCES EXCITATORY TRANSMITTER AMINO-ACID RELEASE FROM THE ISCHEMIC RAT CEREBRAL-CORTEX
    OREGAN, MH
    SIMPSON, RE
    PERKINS, LM
    PHILLIS, JW
    [J]. NEUROSCIENCE LETTERS, 1992, 138 (01) : 169 - 172
  • [34] Peterfreund RA, 1996, J NEUROCHEM, V66, P362
  • [35] PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26
  • [36] The effects of selective A(1) and A(2a) adenosine receptor antagonists on cerebral ischemic injury in the gerbil
    Phillis, JW
    [J]. BRAIN RESEARCH, 1995, 705 (1-2) : 79 - 84
  • [37] PHILLIS JW, 1997, PRIMER CEREBROVASCUL, P250
  • [38] Adenosine A(2A) receptor stimulation enhances striatal extracellular glutamate levels in rats
    Popoli, P
    Betto, P
    Reggio, R
    Ricciarello, G
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 287 (02) : 215 - 217
  • [39] PULSINELLI W, 1993, PROG BRAIN RES, V96, P125
  • [40] Rosin DL, 1998, J COMP NEUROL, V401, P163